Success Metrics

Clinical Success Rate
93.0%

Based on 40 completed trials

Completion Rate
93%(40/43)
Active Trials
8(12%)
Results Posted
33%(13 trials)
Terminated
3(5%)

Phase Distribution

Ph not_applicable
15
23%
Ph phase_2
10
15%
Ph phase_4
18
27%
Ph phase_1
10
15%
Ph phase_3
5
8%
Ph early_phase_1
1
2%

Phase Distribution

11

Early Stage

10

Mid Stage

23

Late Stage

Phase Distribution59 total trials
Early Phase 1First-in-human
1(1.7%)
Phase 1Safety & dosage
10(16.9%)
Phase 2Efficacy & side effects
10(16.9%)
Phase 3Large-scale testing
5(8.5%)
Phase 4Post-market surveillance
18(30.5%)
N/ANon-phased studies
15(25.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.6%

40 of 49 finished

Non-Completion Rate

18.4%

9 ended early

Currently Active

8

trials recruiting

Total Trials

66

all time

Status Distribution
Active(9)
Completed(40)
Terminated(9)
Other(8)

Detailed Status

Completed40
Recruiting8
unknown8
Withdrawn6
Terminated3
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
66
Active
8
Success Rate
93.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.7%)
Phase 110 (16.9%)
Phase 210 (16.9%)
Phase 35 (8.5%)
Phase 418 (30.5%)
N/A15 (25.4%)

Trials by Status

completed4061%
recruiting812%
terminated35%
unknown812%
withdrawn69%
enrolling_by_invitation12%

Recent Activity

Clinical Trials (66)

Showing 20 of 66 trialsScroll for more
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT06731764Phase 2

Novel Approaches to the Treatment of Hypothyroidism

Recruiting
NCT05712421Phase 2

A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism

Completed
NCT01391962Phase 2

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Completed
NCT07380854Not Applicable

Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism

Recruiting
NCT07332273Phase 3

Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity.

Recruiting
NCT06345339Phase 2

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Recruiting
NCT06652113Not Applicable

Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab

Recruiting
NCT06428097Phase 1

Levothyroxine Supplementation for Heart Transplant Recipients

Recruiting
NCT06625814Phase 1

A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)

Completed
NCT05412979Phase 2

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

Completed
NCT05276856

Recovery Rate in Secondary Hypothyroidism

Recruiting
NCT04782856Phase 2

Energy Metabolism in Thyroidectomized Patients

Completed
NCT04124705Phase 2

A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants

Completed
NCT05316922Phase 3

TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients

Recruiting
NCT04288115Phase 4

Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism

Completed
NCT04868045Phase 1

Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer

Withdrawn
NCT02548715Phase 2

Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery

Withdrawn
NCT02577367Phase 4

Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding

Withdrawn
NCT03098433Phase 1

Effects of Liothyronine on Energy Expenditure and Cardiovascular Function

Completed

Drug Details

Intervention Type
DRUG
Total Trials
66